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Abstract
Background: From 2010 to 2014, approximately 2 million Pap smears from HIV-infected women were submitted to
the South African National Health Laboratory Services (NHLS) through the national cervical cancer screening
programme. The objective of this analysis was to determine whether using the plastic Cervex brush (“broom”)
would be a cost-effective approach to improve cytology specimen quality as compared to the wooden spatula
used currently.
Methods: A decision analysis model was built using the expected adequacy rates for samples collected with the
spatula (<$0.02) and broom ($0.23) and the probability of detecting cervical dysplasia. NHLS data was used for
testing volumes and rates of HIV-positivity, suitability of specimens, and presence of endocervical cells. Expected
positivity of Pap smears in HIV-infected women (73 %), odds ratios of the effectiveness of the broom (OR: 1.57), and
improved sensitivity when endocervical cells present (OR: 1.89) are from literature. NHLS costs were used for the
collection devices and conventional cytology ($4.89). Cost of clinic visit is from WHO CHOICE ($8.36).
Results: In 2010, 80 % of specimens submitted to NHLS were adequate for evaluation; in 2014, only 54 % met the
same criteria. For HIV-infected women, according to the guidelines model, using the wooden spatula costs $6.25
million per year, $16.79 per woman tested. Under intended practice, for each additional HSIL case detected among
HIV-infected women, the South African cervical cancer screening programme could save $13.64 (95 % CI: $13.52 to
$13.76) by using the broom as its standard of care collection device through increased collection of endocervical
cells and consequent reduction in repeat Pap smears.
Conclusion: Under a wide range of parameters tested using a simulation model, the more expensive plastic broom
could save the South African cervical cancer screening programme money and increase detection of high-grade
cervical dysplasia in HIV-infected women compared to the current wooden spatula.
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Background
Cervical cancer is the second most common cancer
among women in South Africa, with an estimated in-
cidence of 31.7 per 100,000 [1]. In the same year
(2012), cervical cancer had the highest mortality rate
(18.0 per 100,000 women) of cancers among women
in South Africa [1]. Cervical cancer is caused by infection
with sexually transmitted human papillomavirus (HPV);
there is a growing body of evidence of inter-related risks
and burdens of HPV and HIV. An estimated 6.3 million
persons in South Africa are HIV-infected, women account
for approximately 55 % of prevalent HIV infections [2]. A
recent systematic review confirmed women who are HIV-
infected have a higher incidence of cervical dysplasia, de-
velop cervical dysplasia at an earlier age, are at higher risk
of persistent HPV infection, are likely to develop cervical
dysplasia earlier, and are at a higher risk of progression of
cervical lesions [3]. The conventional Papanicolaou test,
or Pap smear, is the standard of care in the public sector
in South Africa to screen for cervical cancer [4].
Recognizing the higher risks of cervical cancer faced
by HIV-infected women, a dual programme for cervical
screening exists in South Africa. Women who are HIV-
negative should be screened 3 times in their lifetime,
once every 10 years, from age 30 [4]. From April 2010,
the South African guidelines for the management of
adults and adolescents with HIV indicate that from age
18 years, women who are HIV-infected should have a
Pap smear for cervical cancer screening at HIV diagnosis
and, if normal, a repeat Pap smear once every three
years [5]. The National Health Laboratory Services
(NHLS) has maintained a database of all Pap smears
since the start of the HIV screening programme. By the
end of 2010, the NHLS had reviewed 600,688 slides of
cytological specimens collected from across the 4,000
public health clinics and centres in South Africa. More
than 3.6 million slides had been reviewed by the end of
November 2014; an estimated 45 to 55 % of which were
from HIV-infected women. Figure 1 shows the increase
in Pap smears in the South African public sector from
2010 to 2014 as well as the proportion of abnormal
smears detected by year.
The South African cervical cancer screening guidelines
use the Bethesda guidelines to define smear adequacy. In
this system, a slide is considered adequate if it has
proper patient identification, is not irreparably broken,
has 8,000–12,000 well-preserved squamous cells, has at
least 10 well-preserved endocervical or metaplastic cells
and less than 75 % of all cells are obscured by blood or
inflammation [6]. In conventional cytology, the presence
of endocervical or metaplastic cells is one indication that
the transformation zone has been sampled and therefore
that the sample collected is adequate for the detection of
the precursors of cervical cancer [7].
Unfortunately, with the increase in testing volumes in
the South African national cervical cancer screening
programme, there has also been a decrease in the quality
of Pap smears collected, as defined by the absence of
endocervical cells. In 2010, 80.5 % of specimens submit-
ted were evaluated as adequate for evaluation; in 2014,
only 54.4 % of specimens met the same criteria. Figure 2
indicates the decreasing adequacy of specimens over
time. There are multiple reasons for the poor adequacy
rate of Pap smears submitted for conventional cytology
in South Africa – overworked clinic and laboratory staff,
lack of training, task shifting without training, and rapid
increase in volumes of slides submitted. Literature on
quality of Pap smears indicated that adoption of an im-
proved collection device, such as the broom, could im-
prove the collection of endocervical cells.
Fig. 1 Counts of normal and abnormal Pap smears reported in the South African public sector, April 2010 to November 2014
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South African guidelines for Pap smears also indicate
that the recommended device for specimen collection is
the wooden spatula with an elongated tip (Aylesbury
spatula). The NHLS provides the spatula, glass slides,
slide fixative, and laboratory request form to the clinics.
A Cochrane review focusing on cytological specimen
collection devices suggests that the proportion of speci-
mens that are satisfactory for evaluation and include
endocervical cells may be improved if the spatula is re-
placed by either the cytobrush used in combination with
the spatula (odds ratio (OR): 3.48, 95 % confidence inter-
val (95 % CI): 3.20–3.78) or the Cervex-Brush (OR: 1.57,
95 % CI: 1.42–1.73], also known as the ‘broom’ [7]. The
broom has parallel plastic fibres, with longer fibres in
the middle and shorter fibres on the outside so that the
endocervical and ectocervical cells can be collected sim-
ultaneously. The cytobrush (used to collect endocervical
cells) and wooden spatula (used to collect ectocervical
cells) combination involves more steps and consumables
than use of the broom alone, thus the broom is the sim-
pler option to implement. Currently, the elongated-tip
wooden spatula is on public tender, and available for
< $0.02 per spatula while the broom is available from
private medical suppliers at $0.23 per broom. To investi-
gate the potential cost-effectiveness as defined by the
cost per high-grade lesion detected from a provider per-
spective of using the more expensive broom in the South
African national cervical cancer screening programme
for HIV-infected women, we created a decision-analysis
model based both on the intended (guideline) and actual
practice for collection and evaluation of Pap smears
using national-level data from the NHLS and published
research on true rates of positivity. Because of the larger
volume of testing for HIV-infected women, and the
higher risk of infection, persistence of infection and
progression of dysplasia and cervical disease for HIV-




As indicated above, the South African cervical cancer
guidelines define an adequate smear as one where both
ecto- and endocervical cells are present. If any abnor-
mality is seen, results are reported by the laboratory,
even if it does not meet the minimum requirements for
adequacy. According to South African cervical cancer
screening guidelines, women should be recalled for im-
mediate retesting if a negative Pap smear is found to lack
endocervical cells or if it is unsatisfactory for evaluation
because of other reasons, such as blood obscuring the
sample [4]. This guideline differs from contexts where
Pap smears are repeated more frequently, HPV testing
is more widely used, or HIV-infection less prevalent.
The following are considered abnormal Paps in the
South African context: atypical squamous cells: un-
known significance (ASC-US) or cannot exclude HSIL
or high-grade changes (ASC-H); low-grade squamous
intraepithelial lesion (LSIL); high-grade squamous
intraepithelial lesion (HSIL); and squamous cell carcin-
oma. Women with atypical glandular cells of undeter-
mined significance (AGC) are referred for specialist
care. If HSIL or ASC-H [8] is reported, the woman
should be referred for colposcopy or specialist care. Ab-
normal Pap smears which are ASC-US or LSIL should
be repeated the following year and if diagnosis unchanged
(e.g. persistent ASC-US) or worse, the woman should be
referred for colposcopy. Human papillomavirus (HPV)
testing is not routinely available within the South African
public health sector.
Fig. 2 Counts of adequate and inadequate specimens evaluated by the NHLS, April 2010 to November 2014
Schnippel et al. BMC Health Services Research  (2015) 15:499 Page 3 of 10
Model structure
A decision-analysis model was established to represent
intended (guideline) practice for when an HIV-infected
woman has a Pap smear done at a public health facility
in South Africa. Screening guidelines were chosen as the
base model for estimating the cost-effectiveness of the
broom collection device as care that is does not meet
guidelines can be considered ‘substandard’.
Figure 3 shows the guidelines (intended practice)
model. The start of the model is an HIV-infected woman
receiving a Pap smear from a public health facility, she is
either a true negative (normal Pap smear) or true posi-
tive (abnormal Pap smear). In the model, a woman who
has no cervical dysplasia may be correctly diagnosed
with a normal Pap smear, receive a false positive diagno-
sis (depending on the Pap test’s specificity), or be lost to
Fig. 3 Decision analysis model, diagnosis of cervical dysplasia according to South Africa guidelines (intended practice)
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care prior to receiving a diagnosis. Each of these differ-
ent outcomes represents a different ‘branch’ of the
decision-analysis model ‘tree’. A woman with cervical
dysplasia may be correctly diagnosed with an abnormal
Pap smear, receive a false negative diagnosis (depending
on the Pap test’s sensitivity), or be lost to care prior to
receiving a diagnosis. The cervical dysplasia in women
who are not diagnosed (due to false negatives or loss to
care) may regress, persist, or progress prior to her next
Pap smear (3 years). The proportions of women with
true disease, detected abnormal cells, and disease that
progresses are differentiated according to grade: ASC-
US, LSIL and HSIL (including ASC-H). AGC was not
modelled as it represented 0.1 % of reports by the NHLS
from 2010 to 2014.
As noted above, when the laboratory grades the speci-
men as inadequate, the woman should be rescreened.
However, as can be seen in Fig. 3, some women may be
lost-to-follow-up and never return to the clinic for a re-
peat Pap smear. Other women may return to the
clinic, but the Pap smear is not repeated for reasons
related to the clinic (e.g. inadequate staffing or sup-
plies, no electricity, closing time) or reasons related
to the patient (e.g. unwilling to repeat the examin-
ation, no time for repeat examination, menstruating).
As above, the cervical dysplasia in women who are
not diagnosed prior to being lost to care may regress,
persist, or progress prior to her next scheduled Pap
smear (3 years). In this model, a high proportion of
inadequate slides leads to missed opportunities for
diagnosis as women are lost to care. Inadequate slides
also result in an increased burden on the patient,
health care facility, and cytology laboratory from re-
peat testing.
Because of the difficulties in repeating the large number
of Pap smears that are inadequate within the national
programme, in many clinics typical practice differs from
intended practice. Thus, an alternative scenario was con-
structed. We created a decision-analysis model that was
structured to reflect typical practice (Fig. 4). Under typical
practice, as under intended practice, all detected abnor-
malities are reported regardless of whether endocervical
cells are present. However, if no abnormality is reported
the Pap smear is not repeated, regardless of the lack of
endocervical cells, even for women who may be at high
risk of cervical disease. In this model, a high proportion of
inadequate slides leads to a high number of false negative
diagnoses as the sensitivity of Pap smears decreases when
there are no endocervical cells present, as per results of
the Cochrane review (OR: 1.89, CI 95 %: 1.79 – 2.00) [7].
As in the intended practice (guidelines) model, the cer-
vical dysplasia in women who are not diagnosed due to
false negatives may regress, persist, or progress prior to
her next scheduled Pap smear (3 years).
Both models were built in Stata, v13 (College Station,
TX, USA). The estimated probability of a woman at each
outcome (branch) was multiplied by the cost of that out-
come. Uncertainty around model parameters was evalu-
ated using Monte Carlo simulation; 10,000 trials were
run for each models. Mean values for key results were
compared using linear regression. Neither costs nor out-
comes are extended beyond screening for cervical
cancer; the model is intended to provide information on
the decision about the potential incremental cost and
diagnoses though the use of two different collection
devices for Pap smears; the cost-effectiveness of early de-
tection of cervical dysplasia is assumed.
Model parameters
Model parameters for the guidelines and typical prac-
tice models, including mean values, shape of sampled
distribution, and 95 % confidence interval are re-
ported in Tables 1 and 2.
Annual numbers of Pap smears evaluated, the propor-
tion of specimens reported to have been collected from
HIV-infected women, the number of slides with endo-
cervical cells, and the number of slides not suitable for
evaluation were extracted from the NHLS database of
3.6 million slides examined between April 2010 and
November 2014.
True rates of abnormal Pap smears that are expected
from an HIV-infected population at a public sector facil-
ity in South Africa were extracted from literature; sensi-
tivity and specificity of Pap smears collected using
broom with endocervical cells present were taken from
the same study [9]. The proportion of women not
returning to the clinic for a repeat Pap smear was
based on the lost-to-follow-up rate from a South
African study [10]. The rate of repeat Pap smears for
those women who did return to the clinic was
assumed.
Odds ratios of the presence of endocervical cells on
a specimen collected by a broom compared to the
elongated tip spatula and of the rates of detection of
cervical dysplasia from smears with endocervical cells
compared to those without were extracted from a
Cochrane review of cervical collection devices for
standard cytology [7].
Provider costs (costs incurred by the Department of
Health to provide the Pap smear service) were estimated
using WHO CHOICE ingredients-based approach [11].
NHLS provided the costs of the wooden spatula, which
is purchased in large quantities on tender for < $0.02
each. A quotation was obtained for procurement of 100
broom devices for $0.23 each. In addition to the cytology
laboratory test (NHLS charge of $4.89, having excluded
the cost of the collection device), it was assumed that
Pap smears are done within the context of an outpatient
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visit by the woman to a clinic. Therefore, the WHO
CHOICE 2008 USD cost for an outpatient visit to no-
bed public sector facility in South Africa [11] was
inflated to 2014 values using annual consumer price
index for the period [12]. The NHLS charge for a Pap
smear and local quotation for the broom were converted
to USD using the average 2014 exchange rate of ZAR
10.83/USD [13].
Costs for active follow-up of patients needing to be
rescreened, e.g. phone calls or home visits, were ex-
cluded as practice and costs differ by clinic and geog-
raphy of the clinic catchment area. Costs incurred by
patients, e.g. paying for transport to the clinic, or op-
portunity costs for patients to visit the clinic multiple
times, e.g. lost wages, were also excluded as the ana-
lysis is from a provider perspective only.
This study did not involve human subjects; no patient-
level medical data or records were accessed or analysed.
We report all results according to the Consolidated
Health Economic Evaluation Reporting Standards
(CHEERS) statement [14].
Results
Each year, the NHLS receives an average of 723,829
gynaecological slides for conventional cytology; of
these an average 372,340 per year will be from HIV-
infected women.
For HIV-infected women, using the wooden spatula
for specimen collection and implementing cervical can-
cer screening guidelines (intended practice) costs $6.25
million per year, or $16.79 per woman tested (Table 3).
If the Cervex-Brush (broom) were used as the standard
Fig. 4 Decision analysis model, diagnosis of cervical dysplasia, typical practice in South Africa
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collection device, it could save the South African cervical
cancer screening programme $0.67 million per year
(95 % CI: $0.64 to $0.70 million), or $1.81 per woman
tested (95 % CI: $1.79 to $1.82). This 11 % decrease in
cost is obtained through increased collection of endocer-
vical cells and consequent reduction in the need to re-
peat Pap smears. At the same time, use of the broom as
the collection device for Pap smears from HIV-infected
women could result in 7 % more abnormal slides re-
ported, an absolute increase of 14,222 cases (95 % CI:
13,093 to 15,351), based upon the expected true Pap
smear positivity from HIV-infected women. The major-
ity of this increase would comprise of HSIL cases - 6,180
cases per year (8 %, 95 % CI: 5,276 to 6,634) - because of
the increased sensitivity of Pap smears for HSIL when
endocervical cells present. Most of the increase in detec-
tion of abnormalities results from an increase in diagno-
sis (30,837 more women, 95 % CI: 30,640 to 31,033)
compared to high rates of lost to follow-up without re-
peating the Pap smear. Results are sensitive to assumed
rates of women returning to the clinic when recalled
and having a repeat Pap smear once at the clinic. Under
intended practice, for each additional HSIL case detected
among HIV-infected women, the South African cervical
cancer screening programme could save $13.64 (95 %
CI: $13.52 to $13.76) by using the broom as its standard
of care collection device.
For HIV-infected women, according to the typical
practice model, where Pap smears are rarely repeated
even if no endocervical cells present on a normal slide,
using the wooden spatula for specimen collection costs
$5.0 million per year, or $13.46 per woman tested. If the
broom were used as the standard collection device, this
would cost an additional $79,022 per year (95 % CI:
$52,548 to $105,496) or $0.21 per woman tested (+2 %,
95 % CI: $0.20 to $0.22) for the more expensive broom
collection device. At the same time, use of the broom as
the collection device for Pap smears could result in 19 %
more abnormal slides reported, an absolute increase of
32,184 cases (95 % CI: 31,178 to 33,189) per year based
Table 2 Model input parameters. Cost parameters (2014 USD)
used for intended and typical practice models
Parameter Mean Distribution Source
USD/ZAR exchange rate 2014 $ 0.09 Point [13]
Wooden spatula, elongated tip $ 0.02 Point NHLS 2014
Broom (cervex brush, type E) $ 0.22 Point Quotation 2014
Outpatient clinic visit
(no bed facility)
$ 8.36 Point [11], [12]
Laboratory test charges
(excluding collection device)
$ 4.89 Point NHLS 2014
Table 1 Model input parameters. Parameters used for intended and typical practice models
Parameter Mean CI 95 % Distribution Source
p5 p95
Women tested (annual count) 723,829 583,056 869,393 Normal NHLS database
Presence of endocervical cells broom vs spatula, odds ratio 1.57 1.44 1.70 Normal [7]
Probability of detection of atypia/dyskaryosis in smears with
enodcervical cells vs those without, odds ratio
1.89 1.80 1.98 Normal [7]
Probability of detection of severe atypia/dyskaryosis in smears
with enodcervical cells vs those without, odds ratio
2.46 1.75 3.17 Normal [7]
HIV-infected (%) 51 40 64 Binomial NHLS database
HIV-infected women tested (annual count) 372,340 261,707 493,988 Normal Calculated
Abnormal Pap smear (% of all smears) 73 71 75 Binomial [9]
HSIL (% of all smears) 31 29 33 Binomial [9]
LSIL (% of all smears) 37 35 39 Binomial [9]
ASC-US (% of all smears) 5 4 6 Binomial [9]
Endocervical cells present, spatula (% of all smears) 53 52 54 Binomial NHLS database
Endocervical cells present, broom (% of all smears) 83 76 90 Binomial Calculated
Sensitivity (%, if endocervical cells present) 76 72 80 Binomial [9]
Sensitivity (%, if no endocervical cells present) 40 35 45 Binomial Calculated
Sensitivity HSIL (%, if no endocervical cells present) 32 23 44 Binomial Calculated
Repeat Pap smear done (% of patients) 90 85 95 Binomial Assumption
Smear satisfactory for evaluation (% of all smears) 98 98 99 Binomial NHLS database
Specificity (%) 84 81 87 Binomial [9]
Lost to follow-up (% of patients) 8 6 10 Binomial [10]
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upon the expected rates of Pap smear true positivity for
HIV-infected women. The number of HSIL cases de-
tected would increase by 15,295 per year (+24 %, 95 %
CI: 14,900 to 15,689). Using the broom could also result
in a 28 % decline (32,184 fewer women, 95 % CI: 31,619
to 32,748) in the number of women who receive a false
negative diagnosis. Results are sensitive to current rates
of adequacy in the national programme with the use of
the spatula device and the gains in sensitivity of the Pap
in detecting cervical dysplasia on slides with or without
endocervical cells. Under typical practice, the screening
programme could save $14.55 (95 % CI: $14.42 to
$14.68) for each HSIL case detected if the broom was
used.
Discussion
South African HIV treatment guidelines indicate that
HIV-infected women should have a Pap smear every
three years from diagnosis of HIV [5]. With an estimated
3.4 million women living with HIV in South Africa, the
number of Pap smears done each year in the public sec-
tor needs to almost triple from the current average of
372,340 per year. However, previous rapid expansion in
Pap smear coverage corresponded with a decline in
quality. The proportion of slides with endocervical cells
submitted to the NHLS for cytology from public sector
clinics declined, from 80.5 % in 2010 to only 54 % in
2014. The national cervical cancer screening guidelines
set a target for public health facilities to have at least
70 % adequacy rate (slides with endocervical cells
present). The concern is that, with the lower sensitivity
of Pap smears when no endocervical cells are present, ei-
ther a large number of Pap smears must be repeated
(wasteful expenditure) or a large number of women re-
ceive false negative results and the benefits of having a
Pap smear screening programme are not realized.
According to the decision analysis model and Monte
Carlo simulation presented here, although the broom is
more expensive than the wooden spatula currently used,
for the HIV-infected women tested (45–55 % of all
women) the South African cervical cancer screening
programme could save $0.67 million each year by avoid-
ing repeat Pap smears. In both the intended practice and
typical practice models, for the detection of HSIL cases,
the broom is both more effective and less expensive than
the spatula.
The cost of a Pap smear was built from the cost of a
clinic visit, the conventional cytology laboratory charge
and the cost of the collection device. If a nurse spends
more time with a woman to do a Pap smear than with a
patient presenting at the outpatient facility for another
reason, the costs here may be underestimated. This aver-
age cost may also underestimate the costs of serving
those that are hard to reach: a Pap smear in rural com-
munities in South Africa served by a mobile van costs
$46 to $76 instead of the $16.79 estimated here [15]. As
NHLS is a parastatal entity, laboratory charges are stan-
dardized across all public health facilities and are ga-
zetted annually by the national government. Laboratory
charges do not necessarily reflect the costs incurred by
Table 3 Model results
Spatula Broom Incremental difference
Value % 95 % CI
Guidelines (intended practice)
Annual programme cost $ 6,246,919 $ 5,575,183 - $ 671,736 -11 % -$ 702,963 to - $ 640,509
Cost per woman screened $ 16.79 $ 14.98 - $ 1.81 -16 % - 1.82 to -$ 1.79
Cost per HSIL case detected $ 78.91 $ 65.27 -$ 13.64 -21 % -$ 13.76 to -$ 13.52
Abnormal smears detected 204,181 218,403 14,222 7 % 13,093 to 15,351
HSIL smears detected 79,465 85,645 6,180 8 % 5,726 to 6,634
False negative smears reported 63,641 62,377 -1,264 -2 % -1,631 to -897
No diagnosis (lost to care) 43,197 12,361 -30,837 -71 % -31,033 to -30,640
Typical practice
Annual programme cost $ 5,034,091 $ 5,113,113 $ 79,022 2 % $ 52,548 to $ 105,496
Cost per woman screened $ 13.46 $ 13.67 $ 0.21 2 % $ 0.20 to $ 0.22
Cost per HSIL case detected $ 79.60 $ 65.05 -$ 14.55 -18 % -$ 14.68 to - $ 14.42
Abnormal smears detected 172,421 204,604 32,184 19 % 31,178 to 33,189
HSIL smears detected 63,566 78,861 15,295 24 % 14,900 to 15,689
False negative smears reported 116,082 83,898 - 32,184 -28 % -32,748 to 31,619
No diagnosis (lost to care) 1,223 1,223 0 0 % -9 to 9
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the NHLS to provide the service, but do reflect the cost
to the Department of Health and the South African
Treasury. Also, we did not include costs for follow-up of
women to return to the clinic (e.g. calling the woman to
return to the clinic, additional patients in the clinic, time
to explain the need for a repeat visit). One study from
the South African context estimates that this could be
$2.27 to $7.62 per woman traced by the clinic [16]. Loss
to follow-up may be higher than the 8 % used in the
model (range 6–10 %) here, a study in rural South Africa
found that 46 % of women referred for colposcopy did
not attend their appointment [17]. We also only consid-
ered the costs from a provider perspective and did not
include the costs women incur to (repeatedly) present to
the clinic such as transport, lost wages, childcare, or
food at the facility. Thus, both the provider cost and the
societal cost of Pap smears are likely underestimated
here. Further, the wooden spatula is currently on public
tender for procurement of 1 million per year, while the
cost used for the plastic broom was obtained from a
quotation from a private medical supplier. It is likely
that if the broom were procured for the public sector at
the quantities currently required each year that the price
could drop significantly. Therefore, the incremental cost
savings for each woman screened under the intended
practice model is conservative. For the typical practice
model, the incremental cost per woman screened may
be even less than $0.21 (2 %) currently estimated.
The model also presents a conservative view of the
benefits of using the broom: increased detection of
HSIL. Undiagnosed and untreated disease has the po-
tential to progress and create an increasing burden for
the health sector and society through the need to treat
advanced disease and invasive cervical cancer. This is
especially important for HIV-infected women with cer-
vical dysplasia, as they are at a higher risk for persist-
ent disease and faster disease progression [3]. This
potential cost savings – e.g. the savings from not hav-
ing to treat cervical cancer with radiation, chemother-
apy, specialist care and oncology, surgery and palliative
care – is not quantified here.
That said, the model is also limited to the costs and out-
comes of the cervical cancer screening programme, it does
not take into account the increased budget required for
colposcopy or cancer treatment because more women
were detected with cervical dysplasia rather than lost to
care. However, as noted above, it is well established that
identifying and providing early treatment for dysplasia is
cost effective approach to managing cervical disease (i.e.
as compared to managing late state cervical cancer).
One limitation of the study was that this was facility-
level data and not patient-level; therefore, it was not
possible to identify patient characteristics that may have
led to increased risk of poor specimen collection. Thus,
the recommendation has to be at programme level
(adopt the broom for all Pap smears or all Pap smears
for HIV-infected women) rather than for certain women.
This needs more evaluation. Also, because the data was
not patient level, it was not possible to identify whether
the Pap smears recorded were initial or repeat Pap
smears. In the models constructed, the probability that
the repeat Pap would be adequate (satisfactory for evalu-
ation and with endocervical cells present) was assumed
to be independent from the initial Pap. It may be that
women who had an initial inadequate Pap are more
likely to have a second inadequate Pap, as the reasons
for the first were not independent of the woman’s cervix
or the clinic at which she receives care. However, it is
also possible that a woman who had an initial inad-
equate Pap is more likely to have an adequate repeat
Pap as the nurse taking the specimen is more careful on
the repeat test or requests that a more experienced
nurse take this repeat test. On average though, in the
large national programme of cervical screening in South
Africa, 46 % of Pap smears done in 2014 were inad-
equate and we believe that the models constructed can
be used to guide policy as to reducing this number.
Conclusions
Especially in resource-limited settings, policy makers are
under pressure to procure lowest-cost items. Evidence as
to the long-term consequences, including higher overall
cost to the health system, of short-term savings is needed
to change policies. Under a wide range of possible values
for key parameters, the decision analysis model presented
here for intended and typical practice indicate that use of
a $0.22 plastic Cervex-Brush (broom) for collection of gy-
naecological specimens from HIV-infected women is a
cost-effective choice compared to the cheaper wooden
spatula (<$0.02 per device). The improved sensitivity of
conventional Pap smears from better specimen collection
by the broom, e.g. more slides with endocervical cells,
could save the South African cervical cancer screening
programme $13.64 to $14.55 for each case of HSIL de-
tected among HIV-infected women.
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